Curative Biotechnology Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop Study
Boca Raton, FL, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today that it has successfully completed its Investigational New Drug (IND) enabling Tolerance and Toxicology Study of Metformin HCL Solution by Topical Instillation (eye drops) in Rabbits.
Paul Michaels, Chairman and President of Curative Biotechnology, said, “We are pleased to announce the successful completion of these important studies, outlined in our Pre IND meeting with the FDA. We are now able to move on to preparing the Company’s first IND application to move our Metformin reformulation into a clinical trial to treat Intermediate Dry Age-Related Macular Degeneration (AMD) and Geographical Atrophy (GA) resulting from AMD.”
Michaels continued, “Both Dry AMD and GA are currently unmet medical needs with no FDA approved efficacious treatment options. As previously announced, we will be conducting the first in human study under a CRADA (Cooperative Research and Development Agreement) with the National Eye Institute of the National Institutes of Health, in Bethesda Maryland.”
About Macular Degeneration (AMD)
Macular Degeneration is a common eye disorder among people over 50 causing blurred or reduced central vision due from the deterioration of the inner layers of the macula. The macula is the part of the retina that gives the eye clear vision in the direct line of sight. Dry AMD accounts for 80-90% of all age-related macular degeneration (AMD cases), while wet AMD represents 10-20% of patient cases. Currently there are no approved drug treatments for Dry AMD or Geographic Atrophy (late-stage dry AMD).
About Curative Biotechnology, Inc. http://curativebiotech.com
Curative Biotechnology, Inc. (Curative Biotech) is a development stage biomedical company focused on novel therapies for rare diseases. The Company is focused on identifying, acquiring and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. Curative Biotech has ongoing programs in three different therapeutic areas: infectious disease, neuro oncology and degenerative eye disease. The Company’s pipeline includes IMT504, CURB906 and Metformin Reformulation. IMT504 is a novel immune therapy to treat rabies and an adjuvant for vaccines. CURB906 is a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor cancer site to kill the tumor by inhibiting tumor growth and migration of the tumor. Metformin Reformulation is targeting the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD) disease.
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. CUBT is not yet generating revenues. Although forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subjected to known, unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements, including but not limited our ability to generate sufficient market acceptance for our products and services, our ability to generate sufficient operating cash flow, and general economic conditions. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with OTC Markets from time to time which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Curative Biotech (CUBT)
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Zoom to Release Financial Results for the Fourth Quarter and Full Fiscal Year 20231.2.2023 22:05:00 CET | Press release
SAN JOSE, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Zoom Video Communications, Inc. (NASDAQ: ZM) today announced it will release its financial results for the fourth quarter and full fiscal year 2023 on Monday, February 27, 2023, after the market closes. A live Zoom Video Webinar of the event can be accessed at 2:00 pm PT / 5:00 pm ET through Zoom’s investor relations website at https://investors.zoom.us. A replay will be available approximately two hours after the conclusion of the live event. About Zoom Zoom is for you. Zoom is a space where you can connect to others, share ideas, make plans, and build toward a future limited only by your imagination. Our frictionless communications platform is the only one that started with video as its foundation, and we have set the standard for innovation ever since. That is why we are an intuitive, scalable, and secure choice for large enterprises, small businesses, and individuals alike. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and
CORRECTION: Boyden Appoints Distinguished Talent Solutions Leader Chad Hesters President & CEO1.2.2023 20:23:02 CET | Press release
Succession planning for Trina Gordon’s retirement, led by Chairman Craig Stevens, results in marquee hire Chad Hesters New York, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Correction: The original hyperline for "Chad Hesters" was incorrect. This has been rectified. Boyden, a premier leadership and talent advisory firm with more than 70 offices in over 45 countries, is delighted to announce the appointment of Chad Hesters as President & CEO, effective immediately. He takes the reins from Trina Gordon, who retires after 12 years as CEO, 3 years as Chair, and 30+ years as a Managing Partner in the firm. “I am honored to be appointed President & CEO of Boyden,” commented Chad Hesters. “I have long admired Trina Gordon for her leadership and her custodianship of one of the oldest, global heritage brands in our industry. Boyden has a unique, collaborative culture that puts clients at the heart of their business. This collegial community is distinctive and aligns well with my style of engagement in th
Nokia Corporation: Repurchase of own shares on 01.02.20231.2.2023 20:00:00 CET | Press release
Nokia Corporation Stock Exchange Release 1 February 2023 at 21:00 EET Nokia Corporation: Repurchase of own shares on 01.02.2023 Espoo, Finland – On 1 February 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL267,9884.36CEUX32,5604.36AQEU11,2214.35TQEX4,1314.36Total315,9004.36 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 202
HqO Releases 2023 ‘The State of Workplace Experience’ Report1.2.2023 19:18:11 CET | Press release
New research measures shifts in employee sentiment post-pandemic, emphasizing importance of social infrastructure in the workplace BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- HqO, the world’s leading workplace experience platform, today announced the release of its annual “The State of Workplace Experience” report, a research-driven analysis of how the workplace and overall employee sentiment have evolved over the past year and what trends will emerge in 2023 as more workers are called back to the office. Featuring proprietary data from research firms Gartner and Leesman, an HqO company, the 2023 report details a shift in how employees perceive and use the workplace, from an environment where the full scope of their work gets done – focused and individual activities, as well as group meetings – to a space that supports more spontaneous collaboration and interaction. Highlights include: From before the start of the pandemic to 2021-22, the percentage of respondents who said informal socia
REPURCHASE OF SHARES1.2.2023 18:30:00 CET | Press release
REPURCHASE OF SHARES Amsterdam, the Netherlands - Flow Traders Ltd. (“Flow Traders”) (Euronext: FLOW) has repurchased50,431of its own shares in the period from 26 January 2023 up to and including1February 2023 at an average price of €23.41. This is in accordance with the share buyback program originally announced on 22 July 2022 and subsequently increased as per the announcement made on 27 October 2022. The consideration of this purchase was €1.2 million. The total number of shares purchased under this program to date is 1,137,890 shares at an average price of €21.29 for a total consideration of €24.2 million. 3,491,110 shares were held in treasury as at 1 February 2023. Contact Details Flow Traders Ltd. Jonathan Berger / Investor Relations Officer Phone: +31 20 7996149 Email: firstname.lastname@example.org About Flow Traders Flow Traders is a leading global financial technology-enabled liquidity provider in financial products, historically specialized in Exchange Traded Products (